Lord, Abbett & Co. LLC Astrazeneca PLC Transaction History

Lord, Abbett & Co. LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$53.02 - $135.75 $20.7 Million - $53.1 Million	-390,953 Reduced 29.07%	954,130 $52.3 Million
Q2 2022 Aug 12, 2022	BUY	$59.26 - $71.14 $79.7 Million - $95.7 Million	1,345,083 New	1,345,083 $88.9 Million
Q1 2022 May 13, 2022	SELL	$55.72 - $67.12 $1.7 Million - $2.05 Million	-30,474 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$54.02 - $63.83 $46,889 - $55,404	868 Added 2.93%	30,474 $1.78 Million
Q3 2021 Nov 09, 2021	SELL	$55.56 - $60.79 $9,111 - $9,969	-164 Reduced 0.55%	29,606 $1.78 Million
Q2 2021 Aug 11, 2021	BUY	$48.42 - $60.18 $452,727 - $562,683	9,350 Added 45.79%	29,770 $1.78 Million
Q1 2021 May 11, 2021	SELL	$47.16 - $54.44 $64.1 Million - $74 Million	-1,358,880 Reduced 98.52%	20,420 $1.02 Million
Q4 2020 Feb 09, 2021	SELL	$48.52 - $58.02 $15.1 Million - $18 Million	-310,836 Reduced 18.39%	1,379,300 $69 Million
Q3 2020 Nov 12, 2020	BUY	$53.07 - $61.1 $21.8 Million - $25.1 Million	411,008 Added 32.13%	1,690,136 $92.6 Million
Q2 2020 Aug 14, 2020	BUY	$43.1 - $55.31 $54 Million - $69.3 Million	1,252,264 Added 4661.49%	1,279,128 $67.7 Million
Q1 2020 May 14, 2020	BUY	$37.79 - $51.33 $1.02 Million - $1.38 Million	26,864 New	26,864 $1.2 Million

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $200B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

Stay updated on Lord, Abbett & Co. LLC with notifications on news.